Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients

Anti-Cancer Drugs

Volumn 12, Issue 3, 2001, Pages 199-204

  Jagodic, M ^a   Cufer, T ^a   Zakotnik, B ^a   Cervek, J ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Metastatic breast cancer; Oral etoposide; Salvage chemotherapy

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ETOPOSIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDICATION; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; MIDDLE AGED; PATIENT SELECTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035064733     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200103000-00004     Document Type: Article

References (31)

1. Prospective randomized trial of docetaxel versus mitomycin plus viblastine in patients with metastatic breast cancer progressing despite previous anthracycline containing chemotherapy
2. First-line and salvage therapy of metastatic breast cancer with mitomycin/vinblastine
3. Cisplatin plus VP-16 combination chemotherapy in advanced refractory breast cancer
4. Evaluation of the continuous infusion of etoposide plus cisplatin in metastatic breast cancer
5. Response of refractory breast carcinoma to a combination of cisplatin and etoposide
6. Cisplatin and etoposide for advanced breast cancer: A phase II trial
7. Concurrent 72-hour continuous infusion of etoposide and cisplatin in metastatic breast cancer
8. Ifosfamide and platinol combination chemotherapy in advanced breast cancer cisplatin is superior to carboplatin
9. Platinum and etoposide in chemotherapy refractory metastatic breast cancer. A phase II trial of the Italian Oncology Group for Clinical Research
10. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer
11. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment
12. The pharmacology of i.v. and oral etoposide
13. Phase II study of oral etoposide for patients with advanced breast cancer
14. Refractory, breast cancer: A comparison of two different chemotherapy regimens
15. Long-term oral etoposide in metastatic breast cancer. Clinical and pharmacocinetic results
16. Clinical activity of chronic oral etoposide in previously treated MBC
17. Daily oral etoposide in metastatic breast cancer
18. Phase II study of chronic oral etoposide in breast cancer: Preliminary results
19. Chronic oral etoposide in advanced breast cancer
20. Second-line chemotherapy with long-term low-close oral etoposide in patients with advanced breast cancer
21. Salvage KT with oral etoposide in MBC-Preliminary report
22. Cancer of the breast
23. Breast cancer
24. Combination of 5-FU, imidazole carboxamide, BCNU and prednisolone (FIB-P) as a salvage chemotherapy in heavily pretreated breast cancer patients
25. Response to second-line chemotherapy in patients with metastatic breast carcinoma previously responsive to first line treatment
26. Non-parametric estimation from incomplete observations
27. Evaluation of survival data and two new rank order statistics arising in its consideration
28. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: Current status and future prospects
29. A randomized phase II study of Xeloda (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy
30. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
31. Multidrug resistance in clinical practice